In this video, Ursula A. Matulonis, MD, shares that although data from the REFRaME-O1 trial of luveltamab tazevibulin were presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer ...

In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 MIRASOL trial of mirvetuximab soravtansine-gynx for patients with folate receptor alpha-positive, platinum-resistant ovarian ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

The U.S. Federal Drug Administration (FDA) has granted Incyclix Bio Fast Track designation for INX-315 to treat ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors.

In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

A new treatment approach significantly improves survival rates for patients with aggressive, inherited breast cancers, according to researchers. In a trial where cancers were treated with chemotherapy ...

Turning pain into purpose is the aim of a Northland ovarian cancer patient, who hopes a song about her cancer fight will ...

Tilt Biotherapeutics Ltd. has raised $25.6 million in a series B round that will fund phase II development of the lead oncolytic virus in the treatment of platinum-resistant ovarian cancer.

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...